The most common adverse effects include nausea, diarrhea, vomiting, constipation, and abdominal discomfort
These SCFAs activate receptors in the gut, like Free Fatty Acid Receptor 3 (FFAR3) (formerly GPR41), which in turn stimulate the release of GLP-1 and GLP-2
For IBS, BPC-157 alleviates abdominal pain and bloating through its anti-inflammatory properties
The metabolic observations lack longitudinal measurements in the study participants which would be required to evaluate the stability of the biomarkers over time
same patients, same conditions, same time period
Medicare does not cover the anti-obesity medications, and Medicare coverage for the new diabetes drugs is iffy and partial at best, depending on your plan